CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $14.24B, above the global median of $1.18B
- FinancialsAltman Z-Score 4.05: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.07%Below 5Y avg (1.11%)
Annual Rate
EUR 1.60Paid annual
Payout Ratio
25.9%Sustainable
Payback Period
87.2 yr
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.43BEUR14.24B · vs all stocks (USD)
Trailing P/E
23.97xRevenue (TTM)
4.29BEUR4.92B · vs all stocks (USD)
Profit Margin
11.95%Beta
0.3190xvs all stocks
52-Week Change
30.55%vs all stocks
Market Capitalization
12.43BEUR14.24B · vs all stocks (USD)
Enterprise Value
11.18BEUR12.81B · vs all stocks (USD)
Trailing P/E
23.97xForward P/E
10.67xPrice to Sales (TTM)
2.84xPrice to Book (MRQ)
2.59xEnterprise to Revenue
2.61xEnterprise to EBITDA
7.49xProfit Margin
11.95%Operating Margin
28.49%Return on Assets (TTM)
10.28%Return on Equity (TTM)
11.44%Revenue (TTM)
4.29BEUR4.92B · vs all stocks (USD)
Revenue per Share (TTM)
51.99EURUpdated Sep 23, 2026Quarterly Revenue Growth
18.70%Gross Profit (TTM)
3.48BEUR3.98B · vs all stocks (USD)
EBITDA (TTM)
1.58BEUR1.81B · vs all stocks (USD)
Net Income (TTM)
512.60MEUR587.32M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
20.70%Operating Cash Flow (TTM)
1.30BEUR1.49B · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.03BEUR1.18B · vs all stocks (USD)
Trailing Annual Dividend Rate
1.60EURUpdated Sep 23, 2026Trailing Annual Dividend Yield
1.07%vs all stocks
5-Year Average Dividend Yield
1.11%vs all stocks
Payout Ratio
25.89%Minority Interest (Equity)
900.00KEURFY2025 · Dec 31, 2025Revenue
3.93BEURFY2025 · Dec 31, 2025Cost of Goods Sold
750.90MEURFY2025 · Dec 31, 2025Gross Profit
3.18BEURFY2025 · Dec 31, 2025Operating Income
945.10MEUR1.08B · vs all stocks (USD)
Pre-tax Income
578.60MEURFY2025 · Dec 31, 2025Income Tax Expense
133.60MEURFY2025 · Dec 31, 2025Net Income
444.50MEURFY2025 · Dec 31, 2025EBIT
615.50MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.57BEURFY2025 · Dec 31, 2025Research & Development
754.00MEURFY2025 · Dec 31, 2025Selling, General & Administrative
1.16BEURFY2025 · Dec 31, 2025Other Operating Expenses
68.20MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
36.90MEURFY2025 · Dec 31, 2025EPS (Basic)
5.37EURFY2025 · Dec 31, 2025EPS (Diluted)
5.32EURFY2025 · Dec 31, 2025Basic Shares Outstanding
82.65MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
82.65MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
444.50MEURFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.00MEURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
482.40MEURFY2025 · Dec 31, 2025Free Cash Flow
377.10MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.52BEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
444.50MEURFY2025 · Dec 31, 2025Stock-based Compensation
39.30MEURFY2025 · Dec 31, 2025Other Non-cash Items
40.20MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-132.30MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
90.70MEURFY2025 · Dec 31, 2025Capital Expenditures
-105.30MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-223.30MEURFY2025 · Dec 31, 2025Net Acquisitions
-343.60MEURFY2025 · Dec 31, 2025Other Investing Activity
57.00MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-391.90MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
510.20MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-33.70MEURFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-31.60MEURFY2025 · Dec 31, 2025Common Stock Repurchase
-67.70MEURFY2025 · Dec 31, 2025Common Dividends Paid
-116.20MEURFY2025 · Dec 31, 2025Other Financing Charges
5.40MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
266.40MEURFY2025 · Dec 31, 2025Shares Outstanding
82.61MSharesUpdated Sep 23, 2026Float Shares
29.97MSharesUpdated Sep 23, 2026% Held by Insiders
57.64%vs all stocks
% Held by Institutions
21.87%vs all stocks
Total Cash (MRQ)
1.97BEUR2.26B · vs all stocks (USD)
Total Cash per Share (MRQ)
23.91EURUpdated Sep 23, 2026Total Debt (MRQ)
963.10MEUR1.10B · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2044xCurrent Ratio (MRQ)
1.97xBook Value per Share (MRQ)
57.15EURUpdated Sep 23, 2026Total Assets
6.94BEUR7.95B · vs all stocks (USD)
Total Current Assets
2.82BEURFY2025 · Dec 31, 2025Total Liabilities
2.60BEURFY2025 · Dec 31, 2025Total Non-current Assets
4.11BEURFY2025 · Dec 31, 2025Total Non-current Liabilities
1.16BEURFY2025 · Dec 31, 2025Total Current Liabilities
1.44BEURFY2025 · Dec 31, 2025Cash
259.60MEURFY2025 · Dec 31, 2025Cash Equivalents
1.27BEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.53BEURFY2025 · Dec 31, 2025Other Short-term Investments
1.00MEURFY2025 · Dec 31, 2025Accounts Receivable
786.80MEURFY2025 · Dec 31, 2025Inventory
240.90MEURFY2025 · Dec 31, 2025Accounts Payable
854.20MEURFY2025 · Dec 31, 2025Short-term Debt
35.30MEURFY2025 · Dec 31, 2025Other Current Liabilities
28.00MEURFY2025 · Dec 31, 2025Long-term Debt
831.80MEURFY2025 · Dec 31, 2025Other Non-current Liabilities
193.80MEURFY2025 · Dec 31, 2025Common Stock (Book)
83.80MEURFY2025 · Dec 31, 2025Retained Earnings
443.50MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
4.34BEUR4.97B · vs all stocks (USD)
52-Week Low
109.90EURUpdated Sep 23, 202652-Week High
174.00EURUpdated Sep 23, 202652-Week Change
30.55%vs all stocks
Beta
0.3190xvs all stocks
50-Day MA
161.01EURUpdated Sep 23, 2026200-Day MA
153.59EURUpdated Sep 23, 2026Avg 10-Day Volume
104.86KSharesUpdated Sep 23, 2026Avg 30-Day Volume
89.55KSharesUpdated Sep 23, 2026Diluted EPS (TTM)
6.17EURUpdated Sep 23, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.05: safe zoneNotable
Altman Z-Score: 4.05
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $14.24B, above the global median of $1.18BNotable
Market cap (USD): 14,238,638,227.266Global Median: 1,180,223,658.953
Revenue is $4.92B, above the global median of $548.88MNotable
Revenue (USD): 4,916,799,997.993Global Median: 548,883,780.48
Levered free cash flow is $1.18B, above the global median of $18.73MNotable
Levered free cash flow (USD): 1,184,257,536Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Exelixis Inc.
Tier 1ProductionApproval-Gated PipelineRule
Neurocrine Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yunnan Baiyao Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jazz Pharmaceuticals plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sichuan Biokin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Halozyme Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
BridgeBio Pharma, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ALTEOGEN Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sino Biopharmaceutical Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai United Imaging Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Exelixis Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
Doximity Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
The Descartes Systems Group Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth